A new way to target prostate cancer that has stopped responding to treatment
A novel AR degrader in castrate-resistant prostate cancer
This research explores a new type of medicine to help men with prostate cancer that has become resistant to standard hormone therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wayne State University NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-11109522 on NIH RePORTER |
What this research studies
Prostate cancer often becomes resistant to initial hormone treatments, a stage called castrate-resistant prostate cancer (CRPC). In CRPC, the cancer cells often find ways to keep growing, even without much testosterone, often by changing the androgen receptor (AR) protein. This project aims to create a new kind of drug that works by completely removing these problematic AR proteins from cancer cells. These new drugs, called AUTOTACs, are designed to specifically target and break down the AR protein, even the altered versions that resist current medicines. The goal is to offer a new treatment option for patients whose prostate cancer no longer responds to existing therapies.
Who could benefit from this research
Good fit: This research is relevant for men with prostate cancer, particularly those whose disease has progressed to a castrate-resistant stage.
Not a fit: Patients whose prostate cancer is still responding well to existing hormone therapies may not directly benefit from this specific new treatment approach.
Why it matters
Potential benefit: If successful, this new approach could provide a much-needed treatment option for men with advanced prostate cancer that has stopped responding to current hormone therapies.
How similar studies have performed: This project introduces a novel therapeutic platform called AUTOTACs, which represents a new strategy for degrading target proteins, building upon existing knowledge of AR inhibition.
Where this research is happening
Detroit, United States
- Wayne State University — Detroit, United States (Active)
Researchers
- Principal investigator: Kim, Hyeong-Reh Choi — Wayne State University
- Study coordinator: Kim, Hyeong-Reh Choi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.